An editorial by The Lancet aimed to balance hype and hope about the investigational Alzheimer’s drug lecanemab.
The NIH Toolbox Cognition Battery was sensitive to cognitive changes in children and young people with intellectual disability. (Neurology)
Severe COVID-19 was linked with brain changes that mirrored those seen in old age. (Nature Aging)
The FDA’s decision to approve aducanumab (Aduhelm) may have negatively influenced some people’s willingness to participate in early Alzheimer’s trials. (Journal of Alzheimer’s Disease)
Older adults with concurrent vision and hearing impairment had a higher risk of memory decline than those with a single sensory impairment. (Alzheimer’s & Dementia)
Elon Musk’s brain implant company Neuralink is under federal investigation for potential animal-welfare violations. (Reuters)
A novel tool mapped seizures in the brain and may help epilepsy treatment. (Brain)
Gut microbiome changes were linked with Parkinson’s disease. (Nature Communications)
Despite the rising number of recently approved drugs in neurology, use among privately insured patients was limited. (Neurology)
Subjective cognitive decline was linked to dementia risk in cognitively unimpaired Black and Latino patients. (Neurology)
Behold the imagined thoughts of a poet’s mother who died from complications of Alzheimer’s disease. (New York Times)
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsBit.us is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
